NEW YORK (GenomeWeb) – Most patients with advanced EGFR-mutant lung cancer also harbor key secondary mutations within their tumors, according to a new study.

Rather than focus on single gene mutations that might be driving lung cancer, researchers from the University of California, San Francisco, examined whether additional oncogene mutations might occur alongside ones in EGFR and affect patient outcomes.